Orris

🧬 Plasmin β€” Core Concept β€’ Plasmin = enzyme that breaks down fibrin (clot) β€’ Derived from plasminogen (inactive zymogen) β€’ Plasminogen is synthesized in the liver βΈ» βš™οΈ Activation of Plasminogen β†’ Plasmin πŸ”‘ Main activators (VERY HY) 1. tPA (tissue plasminogen activator) β€’ Released from endothelial cells β€’ Most important physiologic activator β€’ Works best when bound to fibrin (clot-specific) 2. uPA (urokinase) β€’ Less important physiologically β€’ Used pharmacologically sometimes βΈ» πŸ’Š Pharmacology (FAVORITE EXAM AREA) Thrombolytics (increase plasmin) β€’ Alteplase β€’ Reteplase β€’ Tenecteplase πŸ‘‰ Mechanism: ↑ conversion of plasminogen β†’ plasmin β†’ fibrin degradation πŸ‘‰ Uses: β€’ Acute ischemic stroke β€’ MI β€’ PE βΈ» 🚫 Inhibitors of Fibrinolysis (ALSO HY) Direct plasmin inhibitors β€’ Tranexamic acid β€’ Aminocaproic acid πŸ‘‰ Mechanism: β€’ Block plasminogen activation β€’ Stabilize clots πŸ‘‰ Uses: β€’ Heavy menstrual bleeding β€’ Post-surgery bleeding β€’ Trauma βΈ» πŸ§ͺ Regulation (Classic USMLE traps) β€’ PAI-1 (plasminogen activator inhibitor) β†’ inhibits tPA & uPA β€’ Ξ±2-antiplasmin β†’ inhibits plasmin directly βΈ» 🎯 Function of Plasmin (WHY IT MATTERS) β€’ Breaks fibrin β†’ fibrin degradation products (FDPs) β€’ Produces D-dimer (VERY commonly tested) πŸ‘‰ Clinical link: β€’ ↑ D-dimer = active clot breakdown (seen in DVT, PE, DIC) βΈ» 🧠 USMLE PEARLS β€’ Clot formation = coagulation cascade β€’ Clot breakdown = fibrinolysis (plasmin-driven) β€’ tPA acts on fibrin-bound plasminogen β†’ clot-specific action β€’ Tranexamic acid = antifibrinolytic (opposite of tPA) Makes notes you can add more cincept usmle based flowchart

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Loading Image
Loading Image
Finding Sources
Both diagrams are excellent. Now I have everything needed to build a comprehensive, USMLE-focused enhanced note. Here it is:

🧬 Fibrinolysis & Plasmin β€” Enhanced USMLE Notes

πŸ”‘ Core Concept

TermDefinition
PlasminogenInactive zymogen β†’ synthesized by the liver
PlasminActive enzyme β†’ cleaves fibrin β†’ fibrin degradation products (FDPs)
FibrinolysisThe physiologic system that dissolves clots to restore vascular patency
Plasmin is the "thrombin equivalent" of the fibrinolytic system β€” just as thrombin drives clot formation, plasmin drives clot dissolution. β€” Harrison's Principles of Internal Medicine 22E

βš™οΈ Activation Flowchart

FIBRIN CLOT FORMS
        β”‚
        β–Ό
Plasminogen binds to fibrin (via lysine-binding sites)
        β”‚
        β–Ό
tPA released from endothelial cells β†’ also binds fibrin
        β”‚
        β–Ό
TERNARY COMPLEX: Fibrin + Plasminogen + tPA
        β”‚  ← greatly accelerates activation
        β–Ό
Plasminogen ──tPA/uPA──► PLASMIN
        β”‚
        β–Ό
Fibrin cleaved β†’ FDPs + D-DIMER
"The assembly of a ternary complex, consisting of fibrin, plasminogen, and tPA, promotes the localized interaction between plasminogen and tPA and greatly accelerates the rate of plasminogen activation to plasmin." β€” Harrison's 22E, p. 515
Key insight: Partial fibrin degradation by plasmin exposes new lysine residues β†’ more plasminogen/tPA binding sites β†’ self-amplifying loop. This is why the reaction is fibrin-specific and self-amplifying at the clot surface.

πŸ“Š Master Diagram β€” Fibrinolytic System

Fibrinolytic system showing tPA, uPA, PAI, plasminogen, plasmin, Ξ±β‚‚PI, and FDPs
FIGURE 69-4 β€” Harrison's Principles of Internal Medicine 22E: tPA is released from endothelial cells, binds fibrin, and activates plasminogen β†’ plasmin. PAI-1/PAI-2 inhibit tPA and uPA. Free plasmin is quenched by Ξ±β‚‚-antiplasmin. FDPs are released.

πŸ”¬ Molecular Mechanism β€” D-dimer Formation

Fibrinolysis cascade showing cross-linked fibrin β†’ plasminogen binding β†’ D-dimer formation
Lippincott Illustrated Reviews Biochemistry 8e, Fig. 35.19: Plasmin cleaves cross-linked fibrin (D–E–D structure) β†’ FDPs + D-dimer (two cross-linked D domains). tPA and plasmin are released from the clot upon completion.
Why D-dimer is specific for cross-linked fibrin:
  • Plasminogen cleaves the Arg560–Val561 bond of plasminogen
  • When plasmin acts on Factor XIIIa cross-linked fibrin β†’ releases D-dimers (two D domains covalently bound)
  • D-dimer is NOT produced from fibrinogen β†’ clot-specific marker

πŸ’Š Pharmacology β€” Full USMLE Map

Thrombolytics (Pro-fibrinolytic)

DrugMechanismHalf-lifeClinical Use
Alteplase (tPA)Recombinant tPA; fibrin-specific~5 minIschemic stroke ≀4.5h, STEMI, massive PE
Reteplase (rPA)Mutant tPA; double IV bolus~18 minSTEMI
Tenecteplase (TNK)Mutant tPA; single weight-based bolus~20 minSTEMI
StreptokinaseNon-fibrin-specific; binds plasminogen~30 minSTEMI (older agent)
"These drugs all act by promoting the conversion of plasminogen to plasmin, which subsequently lyses fibrin thrombi." β€” Harrison's 22E
tPA dosing pearl (STEMI): 15 mg bolus β†’ 50 mg over 30 min β†’ 35 mg over 60 min
Fibrin-specificity distinction:
  • tPA, rPA, TNK = fibrin-specific (preferentially activate fibrin-bound plasminogen)
  • Streptokinase = non-fibrin-specific (systemic fibrinolysis β†’ higher bleeding risk)
TIMI Flow Grading (exam favorite):
  • Grade 0 = complete occlusion
  • Grade 1 = contrast penetrates but no distal perfusion
  • Grade 2 = perfusion but flow delayed
  • Grade 3 = full perfusion, normal flow ← goal of thrombolysis

Antifibrinolytics (Anti-fibrinolytic)

DrugMechanismUses
Tranexamic acid (TXA)Lysine analog β†’ blocks plasminogen lysine-binding sites on fibrin β†’ prevents plasminogen activationHMB, trauma hemorrhage, surgical bleeding, hemophilia
Ξ΅-Aminocaproic acidSame mechanism as TXA (lysine analog)Same uses; longer infusion required
Mechanism deep dive: Both are lysine analogs β€” they compete with fibrin for plasminogen's lysine-binding sites, preventing the Fibrin-Plasminogen-tPA ternary complex from forming β†’ no plasmin generation β†’ clot stabilization
"Both lysine analog plasmin inhibitors (epsilon-aminocaproic acid and tranexamic acid) have been used [as antifibrinolytics]." β€” Barash Clinical Anesthesia 9e

🚫 Physiologic Inhibitors β€” USMLE Traps

INHIBITOR          TARGET           RESULT
─────────────────────────────────────────────────────
PAI-1 (PAI-2)   β†’ tPA + uPA      β†’ ↓ plasminogen activation
                   (endothelial/  
                   platelet release)

Ξ±β‚‚-Antiplasmin  β†’ Free plasmin   β†’ Quenches any plasmin
                                    escaping the clot
PAI-1 Mnemonics:
  • PAI-1 is upregulated by thrombin (pro-coagulant state amplifies its own protection)
  • PAI-1 ↑ in metabolic syndrome β†’ thrombotic tendency
  • PAI-1 excess = impaired fibrinolysis β†’ DVT/PE risk

πŸ§ͺ D-dimer β€” Clinical Correlations

ConditionD-dimerReason
DVT / PE↑↑Active fibrin clot breakdown
DIC↑↑↑Massive simultaneous clotting + fibrinolysis
Pregnancy↑ (physiologic)Increased fibrinogen turnover
Post-surgery↑Expected (limits utility)
NormalLowRules out PE/DVT with high sensitivity
High-yield trap: D-dimer has high sensitivity, low specificity β†’ good for ruling OUT PE/DVT (negative predictive value), NOT ruling IN.

🎯 USMLE Flowchart β€” Coagulation vs. Fibrinolysis

VESSEL INJURY
      β”‚
      β”œβ”€β”€β–Ί COAGULATION CASCADE
      β”‚         β”‚
      β”‚         β–Ό
      β”‚    Thrombin β†’ Fibrinogen β†’ FIBRIN CLOT
      β”‚
      └──► FIBRINOLYTIC SYSTEM (counter-regulation)
                β”‚
                β–Ό
           tPA (from endothelium) β†’ binds fibrin
                β”‚
                β–Ό
           Plasminogen β†’ PLASMIN
                β”‚
                β”œβ”€β”€ Cleaves fibrin β†’ FDPs + D-dimer
                β”‚
                └── Inhibited by:
                     β€’ Ξ±β‚‚-antiplasmin (direct)
                     β€’ PAI-1 (blocks tPA/uPA)
                     β€’ TXA / aminocaproic acid (drug)

⚑ Contraindications to Thrombolytics (USMLE List)

Absolute Contraindications
Prior intracranial hemorrhage (any time)
Ischemic stroke within prior 3 months (for STEMI; ≀4.5h window for AIS)
Suspected aortic dissection
Active internal bleeding (not menses)
Significant closed-head trauma / facial trauma within 3 months
Intracranial neoplasm
Relative Contraindications
BP >180/110 on presentation
Current anticoagulation use
Pregnancy
Traumatic or prolonged CPR (>10 min)
Major surgery within 3 weeks

🧠 High-Yield USMLE Pearls Summary

PearlDetail
tPA mechanismFibrin-bound β†’ ternary complex β†’ localized plasmin generation
Why tPA is "fibrin-specific"Binds fibrin first β†’ only activates fibrin-bound plasminogen
D-dimer sourceCross-linked fibrin only (not fibrinogen) β†’ clot-specific
TXA mechanismLysine analog β†’ blocks plasminogen binding to fibrin
PAI-1 roleInhibits tPA + uPA; upregulated by thrombin β†’ clot stabilization
Ξ±β‚‚-antiplasminQuenches free plasmin in circulation β†’ prevents systemic lysis
Streptokinase vs tPAStreptokinase = non-fibrin-specific β†’ systemic fibrinolysis
Alteplase stroke window≀4.5 hours from symptom onset
Aminocaproic acidSame mechanism as TXA; less potent, longer infusion
Sources: Harrison's Principles of Internal Medicine 22E (Fig. 69-4, pp. 514–516); Lippincott Illustrated Reviews: Biochemistry 8e (Fig. 35.19); Barash Clinical Anesthesia 9e; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.